and independent laboratories shows that one ranitidine 300 mg tablet can contain tens of thousands of nanograms (ng) of NDMA, greatly exceeding the FDA’s daily acceptable intake limit of 96 ng ...

British pharmaceutical company GSK said Wednesday it has agreed to pay $2.3 billion in the United States to put an end to lawsuits alleging that its Zantac heartburn drug caused cancer. "GSK today ...

GSK has agreed to pay up to $2.2 billion to resolve approximately 80,000 lawsuits brought by users of Zantac who claimed the heartburn drug caused their cancer. The agreement frees the British ...

GSK has agreed to pay up to $2.2 billion to settle most lawsuits in US state courts claiming that a discontinued version of the heartburn drug Zantac caused cancer, the company announced on ...

GSK Plc said it will pay as much as $2.2 billion to resolve about 80,000 US court cases related to allegations that its old reflux medication Zantac was contaminated with a suspected carcinogen.

The British pharmaceutical giant said Wednesday that it had struck agreements with 10 plaintiff firms aimed at resolving 93%, or about 80,000, of pending Zantac lawsuits in the country for up to ...

GSK has reached a $2.2bn settlement to resolve the vast majority of cases linked to its heartburn medicine Zantac, in a move that will help assuage legal concerns overhanging the UK drugmaker.

GSK agreed to pay $2.2 billion to 10 plaintiff firms over liability cases related to its discontinued heartburn medicine Zantac allegedly causing cancer. The British pharmaceutical giant said ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

GSK has reached agreements with 10 plaintiff firms to settle around 80,000 state court product liability cases related to its heartburn medication, Zantac, for $2.2 billion. The agreements involve ...